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303 Retinal screening in Wales − A real eye opener!
R. Roberts1, L. Speight1, J. Lee1, R.I. Ketchell1, D. Lau1, J. Duckers1. 1University
Hospital Llandough, All Wales Adult Cystic Fibrosis Centre, Penarth, United
Kingdom
The National Screening Committee suggests annual retinal screening for all diabetic
patients over the age of 12 years. Currently in the All Wales Adult CF service we
arrange annual retinopathy screening for all patients on insulin therapy in their
locality.
Objective: To review the prevalence of diabetic retinopathy and maculopathy in
adult CF patients on insulin therapy and predictors of retinopathy/maculopathy. To
also review uptake of annual retinopathy screening appointments.
Method: Age, sex, FEV1%, BMI, HbA1c, number of years on insulin, presence
of retinopathy/maculopathy and attendance rate at retinal screen were examined for
the year 2012.
Results: 67 (40 female) of the 228 (29%) patients attending our centre in 2012 were
receiving insulin therapy. The mean age (SD) and FEV1% were 29.3 years (9.1)
and 57.9 (24.7) respectively. The mean (SD) HBA1c and BMI were 60.8 (18.4) and
22.2 (2.9) respectively. 43 of the 67 (64%) had a retinal screen in the last year of
whom 18 (42%) had evidence of retinopathy (6 mild, 9 moderate, 2 preproliferative,
1 proliferative) and 6 also had maculopathy. Patients with retinopathy had higher
HBA1c (69.4 p = 0.04) and mean number of years on insulin (10.7 years p< 0.001)
than those without retinopathy.
36% of the patients on insulin did not attend screening in the last year. Age, sex
and FEV1% did not predict attendance at retinal screen.
Conclusions: Almost half the patients who attended screening had evidence of
retinopathy. Over a third of patients did not attend screening appointments in 2012
suggesting we are missing an important treatable microvascular complication which
will become more important in an ageing CF population.
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Large artery haemodynamics are abnormal in adults with CF [1] but have not
been explored in children. Carotid-femoral Pulse Wave Velocity (cfPWV) is a
gold standard and independent measure of future risk in older subjects whilst
augmentation index (AIx), a composite marker of arterial stiffness and wave
reﬂection, is more closely associated with cardiovascular risk factors in younger
subjects.
Objectives: To measure large artery haemodynamics in children with CF and assess
relationship to renal function (GFR), lung function, high sensitivity CRP (hsCRP)
and Interleukin-6 (IL-6).
Methods: CfPWV and AIx were measured in stable children with CF using
applanation tonometry. GFR was measured by Chromium EDTA method. Lung
function was assessed by spirometry and circulating hsCRP and IL-6 levels were
measured.
Results: With 28 participants (mean age 11.3 yrs., range 8.2–14.9), the mean
supine AIx and PWV, adjusted for confounders, were 7.96% (SD 2.17) and
4.78m/s (0.32) respectively. AIx was signiﬁcantly greater (P< 0.0001, 95%CI 3.57
to 7.55) compared to previously published data [2] in children without lung disease
(mean age 11.2 yrs). This was not manifest in standard peripheral BP. There was
no signiﬁcant association of AIx or PWV with GFR, lung function, log10 hsCRP
or log10 IL-6.
Conclusion: Increased AIx is present in children with CF, which is not explained
by renal function, spirometry or the inﬂammatory markers measured. Evidence of
early changes in the haemodynamics in children with CF warrants further research
to explore pathogenesis in order to halt further progression.
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Objectives: Although vitamin B12 is water soluble, there is potential for people
with CF to be deﬁcient, in particular if the terminal ileum has been resected, as
part of neonatal surgery for meconium ileus. Some UK centres have advocated the
routine monitoring of vitamin B12 levels. In this study, we investigated whether
routine red blood cells parameters might be a useful tool to identify macrocytosis
relating to vitamin B12 deﬁciency.
Methods: Retrospective case note review. The full blood count from each annual
review was recorded to measure trends in Mean Cell Volume (MCV), Mean Corpus-
cular Haemoglobin (MCH) and Mean Cell Haemoglobin Concentration (MCHC).
Conclusion: 83 children attending the Alder Hey Children’s Hospital were included
(16 of whom had undergone neonatal MI surgery). A further 35 network patients
who had undergone neonatal MI surgery were included. There was no difference in
MCV between the children who had neonatal surgery for meconium ileus (51) and
those children who had no surgery. A signiﬁcant proportion of older children in the
non-surgery group (19%) had a MCV that was consistently higher than the normal
range. We identiﬁed no overt cases of macrocytic anaemia, but the consistent ﬁnding
of mean cell volumes outside the normal range has prompted further investigation
of these children and highlights the potential of this straightforward strategy to
identify subclinical deﬁciency. We approached 16 UK Paediatric CF centres; four
were routinely recording MCV and one was routinely measuring vitamin B12. We
recommend that centres routinely record MCV at annual review and consider further
assessment of B12 status as required.
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Objectives: To compare actual and patient perceived uptake of inﬂuenza and
pneumococcal vaccination in the adult patients receiving care at the All Wales
Adult CF centre to WHO targets.
Methods: All patients attending for Annual review were asked if they had received
inﬂuenza and pneumococcal vaccinations and to recall month/year of vaccination.
Patients’ GP were contacted to check record of vaccination administration.
Results: 228 patients (123 male), mean age (SD) 28.1 years (9.3) were included and
100% of GP vaccination records were obtained. 169 (74%) patients had received
inﬂuenza vaccine within the last year which falls just short of WHO (and Welsh
Government) target of 75% in at risk groups. Of the 59 patients who did not receive
the inﬂuenza vaccine 36 (61%) either thought they had received it or were unsure.
132 (58%) had received pneumococcal vaccine with a mean (SD) duration since
receiving the vaccine of 5.5 (4.6) years. Of the 96 patients who had never received
the vaccine 77 (80%) either thought they had received it or were unsure.
Age, sex and FEV1% predicted were not predictors of inﬂuenza or pneumococcal
vaccination uptake (p> 0.05).
Conclusion: Recent Cochrane reviews of inﬂuenza and pneumococcal vaccination
in patients with CF illustrate the paucity of evidence in this area. Currently it
remains advised to follow immunisation schedules/targets and with an inﬂuenza
vaccine uptake of 74% we are close to WHO targets. Interestingly a signiﬁcant
proportion of patients who had not received the vaccines thought they had had it
or were unsure and this would have gone unnoticed had the GP vaccination record
not been sought.
